[go: up one dir, main page]

AR072571A1 - Composiciones monovalentes para union a cd28 y procedimientos de uso - Google Patents

Composiciones monovalentes para union a cd28 y procedimientos de uso

Info

Publication number
AR072571A1
AR072571A1 ARP090102734A ARP090102734A AR072571A1 AR 072571 A1 AR072571 A1 AR 072571A1 AR P090102734 A ARP090102734 A AR P090102734A AR P090102734 A ARP090102734 A AR P090102734A AR 072571 A1 AR072571 A1 AR 072571A1
Authority
AR
Argentina
Prior art keywords
domain
activity
domain antibody
union
procedures
Prior art date
Application number
ARP090102734A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Domantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41226147&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR072571(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co, Domantis Ltd filed Critical Bristol Myers Squibb Co
Publication of AR072571A1 publication Critical patent/AR072571A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)

Abstract

Anticuerpos de dominio que se unen de forma monovalente a CD28. Los anticuerpos de dominio que son monovalentes para la union a CD28 pueden inhibir la actividad de CD28. En un aspecto, un anticuerpo de dominio está constituido por o comprende un dominio variable de inmunoglobulina unico que se une específicamente y antagoniza la actividad de CD28 y, en un aspecto, sin agonizar sustancialmente la actividad de CD28. En otro aspecto, el anticuerpo de dominio es un anticuerpo de dominio humano. La descripcion incluye adicionalmente procedimientos para antagonizar las interacciones de CD80 y/o CD86 con CD28 en un individuo y procedimientos para tratar enfermedades o trastornos que implican interacciones de CD80 y/o CD86 con CD28, implicando los procedimientos la administracion de un anticuerpo de dominio al individuo.
ARP090102734A 2008-07-18 2009-07-17 Composiciones monovalentes para union a cd28 y procedimientos de uso AR072571A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8207808P 2008-07-18 2008-07-18
US16212109P 2009-03-20 2009-03-20

Publications (1)

Publication Number Publication Date
AR072571A1 true AR072571A1 (es) 2010-09-08

Family

ID=41226147

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090102734A AR072571A1 (es) 2008-07-18 2009-07-17 Composiciones monovalentes para union a cd28 y procedimientos de uso

Country Status (29)

Country Link
US (6) US8168759B2 (es)
EP (2) EP2321352B1 (es)
JP (3) JP5675608B2 (es)
KR (2) KR101660057B1 (es)
CN (2) CN102159590A (es)
AR (1) AR072571A1 (es)
AU (1) AU2009270726B2 (es)
CA (1) CA2731220C (es)
CL (2) CL2011000117A1 (es)
CO (1) CO6341641A2 (es)
CY (1) CY1121796T1 (es)
DK (2) DK2321352T3 (es)
EA (1) EA024585B1 (es)
ES (2) ES2562629T3 (es)
HR (2) HRP20160329T1 (es)
HU (2) HUE029982T2 (es)
IL (2) IL210413A (es)
LT (1) LT2700651T (es)
ME (1) ME02396B (es)
MX (1) MX2011000501A (es)
NZ (1) NZ590343A (es)
PE (2) PE20110385A1 (es)
PL (2) PL2321352T3 (es)
PT (2) PT2700651T (es)
RS (2) RS58904B1 (es)
SI (2) SI2700651T1 (es)
SM (2) SMT201900367T1 (es)
TW (2) TWI450725B (es)
WO (1) WO2010009391A1 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2949668B1 (en) 2005-05-18 2019-08-14 Ablynx N.V. Improved nanobodies tm against tumor necrosis factor-alpha
US20110097339A1 (en) * 2008-07-18 2011-04-28 Domantis Limited Compositions monovalent for CD28 binding and methods of use
CN102159590A (zh) 2008-07-18 2011-08-17 百时美施贵宝公司 Cd28结合为单价的组合物及使用方法
CN104017778A (zh) * 2009-02-25 2014-09-03 内克斯特伊拉股份公司 不依赖信号序列的pIX噬菌体展示
FR2951176A1 (fr) * 2009-10-09 2011-04-15 Tcl Pharma Ligands monovalents du recepteur cd28 humain
EP2361935A1 (en) * 2010-02-18 2011-08-31 TcL Pharma Anti-CD28 humanized antibodies
CA2788544C (en) 2010-02-18 2019-03-05 Effimune Anti-cd28 humanized antibodies
WO2011156328A1 (en) * 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
JP5768022B2 (ja) * 2012-03-19 2015-08-26 株式会社東芝 メモリコントローラ、記憶装置、誤り訂正装置および誤り訂正方法
WO2014120916A1 (en) 2013-02-01 2014-08-07 Bristol-Myers Squibb Company Pegylated domain antibodies monovalent for cd28 binding and methods of use
IL296754A (en) * 2013-12-27 2022-11-01 Chugai Pharmaceutical Co Ltd A method for isolating an antibody with a low isoelectric point
CN106132429A (zh) * 2014-03-19 2016-11-16 百时美施贵宝公司 使用针对cd40l的域抗体治疗移植物排斥的方法
MX2017003123A (es) 2014-09-12 2017-05-12 Genentech Inc Anticuerpos y conjugados modificados geneticamente con cisteina.
ES2783448T3 (es) * 2014-09-30 2020-09-17 Bristol Myers Squibb Co Métodos de tratamiento del lupus eritematoso sistémico utilizando un anticuerpo de dominio dirigido contra CD28
WO2017160975A1 (en) 2016-03-16 2017-09-21 Bristol-Myers Squibb Company Methods of diagnosing and treating lupus
WO2018106931A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
CA3054632A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
TW202515920A (zh) 2017-04-11 2025-04-16 美商因荷布瑞克斯生物科學公司 具有經受限cd3結合的多重特異性多肽構築體及使用其之方法
US12139534B2 (en) 2018-03-15 2024-11-12 Biond Biologics Ltd. Methods and compositions for decreasing soluble immune receptor CD28
KR20210006913A (ko) 2018-04-11 2021-01-19 인히브릭스, 인크. 제한된 ｃｄ3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 관련된 방법 및 용도
CN112638375A (zh) 2018-06-15 2021-04-09 旗舰创业创新五公司 通过后细胞信号传导因子的调节来增加免疫活性
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
AU2019288635A1 (en) 2018-06-22 2021-01-21 Junten Bio Co., Ltd. Antibody inducing immune tolerance, induced lymphocyte, and cell therapy agent therapeutic method using induced lymphocyte
JP7332691B2 (ja) * 2018-07-08 2023-08-23 スペシフィカ インコーポレイティド 抗体の開発可能性が最大化された抗体ライブラリー
TW202035451A (zh) 2018-07-24 2020-10-01 美商英伊布里克斯公司 含有受限cd3結合域及受體結合區之多重特異性多肽構築體及其使用方法
US12385913B2 (en) 2018-08-03 2025-08-12 Bristol-Myers Squibb Company Methods for detecting anti-drug antibodies
CN116726361A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
EP3938397A1 (en) * 2019-03-14 2022-01-19 Biond Biologics Ltd. Small shedding blocking agents
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
ES2821599A1 (es) * 2019-10-24 2021-04-26 Univ Del Pais Vasco / Euskal Herriko Unibertsitatea Compuestos y metodos para el tratamiento de la enfermedad de alzheimer
US20230041599A1 (en) * 2019-12-02 2023-02-09 Biond Biologics Ltd. Use of mmp inhibition
US11707610B2 (en) 2019-12-13 2023-07-25 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2021127217A1 (en) 2019-12-17 2021-06-24 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
MX2022009306A (es) * 2020-01-29 2022-09-26 Inhibrx Inc Loseta de nucleo de espuma densificada (dfc) con linea de anticuerpos de dominio individual de cd28 y constructos multivalentes y multiespecíficas de los mismos.
EP4172323A1 (en) 2020-06-29 2023-05-03 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
WO2022031695A1 (en) * 2020-08-04 2022-02-10 Exelixis, Inc. Pd-l1 binding agents and uses thereof
KR20230165276A (ko) 2021-03-31 2023-12-05 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션 폴리펩티드 및 암의 치료에서의 이의 용도
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
IL311275A (en) * 2021-09-06 2024-05-01 Biond Biologics Ltd Materials that block and/or screen c. 28 is enough
TW202400659A (zh) * 2022-05-04 2024-01-01 美商詹努克斯治療有限公司 經腫瘤活化之靶向ｃｄ２８及ｐｄ－ｌ１之多特異性抗體及其使用方法
WO2023215560A1 (en) 2022-05-05 2023-11-09 Atoosa Corporation Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp)
WO2023215498A2 (en) * 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
EP4572772A1 (en) 2022-08-17 2025-06-25 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
CN120322459A (zh) 2022-10-06 2025-07-15 比卡拉治疗股份有限公司 多特异性蛋白及相关方法
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024211211A1 (en) 2023-04-03 2024-10-10 Regeneron Pharmaceuticals, Inc. Methods of improving transplant survival using il-2 receptor gamma chain antibodies
WO2024249954A1 (en) 2023-05-31 2024-12-05 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839295A (en) 1984-06-08 1989-06-13 Pierce Chemical Company Measurement of protein using bicinchoninic acid
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2046830C (en) 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
DE69330523D1 (de) 1992-08-21 2001-09-06 Vrije Universiteit Brussel Bru Immunoglobuline ohne leichte ketten
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
GB9416721D0 (en) 1994-08-18 1994-10-12 Short Brothers Plc A bias yarn assembly forming device
JP4979843B2 (ja) 1995-03-10 2012-07-18 ロッシュ ディアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング 微粒子の形のポリペプチド含有投薬形
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
EP0988321A2 (en) 1997-06-20 2000-03-29 Innogenetics N.V. B7-binding molecules for treating immune diseases
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
JP2002512182A (ja) 1998-04-20 2002-04-23 ジェンザイム・コーポレーション ポリマーブレンドから蛋白質のドラックデリバリー
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
AU4770300A (en) 1999-05-14 2000-12-05 Medical Research Council Protein scaffold and its use to multimerise monomeric polypeptides
US20020006403A1 (en) * 1999-12-14 2002-01-17 Xue-Zhong Yu CD28-specific antibody compositions for use in methods of immunosuppression
EP1345969B1 (fr) * 2000-12-26 2010-08-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anticorps anti-cd28
US20080095774A1 (en) * 2001-02-16 2008-04-24 Wyeth Agents and Methods for Specifically Blocking CD28-Mediated Signaling
US7531168B2 (en) 2001-02-16 2009-05-12 Genetics Institute Llc Method for downmodulating immune response in type I diabetes
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
WO2003002609A2 (en) 2001-06-28 2003-01-09 Domantis Limited Dual-specific ligand and its use
ES2337986T3 (es) 2001-08-10 2010-05-03 Aberdeen University Dominios de union de antigenos de peces.
WO2003031611A2 (en) 2001-10-05 2003-04-17 Cangene Corporation Phagemid display system
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
DE10156482A1 (de) * 2001-11-12 2003-05-28 Gundram Jung Bispezifisches Antikörper-Molekül
AU2003244817B2 (en) 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
JP2006519763A (ja) 2002-11-08 2006-08-31 アブリンクス エン．ヴェー． 治療用ポリペプチドの投与法およびそのためのポリペプチド
AU2003290330A1 (en) 2002-12-27 2004-07-22 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
EP1629012B1 (en) 2003-05-31 2018-11-28 Amgen Research (Munich) GmbH Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
AU2004284090A1 (en) 2003-10-24 2005-05-06 Avidia, Inc. LDL receptor class A and EGF domain monomers and multimers
CN100376599C (zh) * 2004-04-01 2008-03-26 北京安波特基因工程技术有限公司 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体
ZA200702427B (en) * 2004-09-17 2008-12-31 Domantis Ltd Compositions monovalent for CD40L binding and methods of use
GB0614093D0 (en) 2006-07-14 2006-08-23 Bae Systems Plc Deployable antenna system
US8907065B2 (en) * 2006-12-15 2014-12-09 Ablynx N.V. Polypeptides that modulate the interaction between cells of the immune system
CN102159590A (zh) * 2008-07-18 2011-08-17 百时美施贵宝公司 Cd28结合为单价的组合物及使用方法
RU2011110459A (ru) 2008-08-21 2012-09-27 Октафарма АГ (CH) Рекомбинантно полученный человеческий фактор viii и ix
CN106132429A (zh) * 2014-03-19 2016-11-16 百时美施贵宝公司 使用针对cd40l的域抗体治疗移植物排斥的方法
ES2783448T3 (es) * 2014-09-30 2020-09-17 Bristol Myers Squibb Co Métodos de tratamiento del lupus eritematoso sistémico utilizando un anticuerpo de dominio dirigido contra CD28

Also Published As

Publication number Publication date
US8454959B2 (en) 2013-06-04
EP2700651A1 (en) 2014-02-26
JP5675608B2 (ja) 2015-02-25
DK2321352T3 (en) 2016-04-04
US20130109846A1 (en) 2013-05-02
CN102159590A (zh) 2011-08-17
KR101791372B1 (ko) 2017-10-27
ES2730727T3 (es) 2019-11-12
NZ590343A (en) 2012-10-26
JP5876134B2 (ja) 2016-03-02
CN105936648B (zh) 2020-06-16
MX2011000501A (es) 2011-05-23
HUE029982T2 (en) 2017-04-28
AU2009270726B2 (en) 2015-07-09
WO2010009391A1 (en) 2010-01-21
DK2700651T3 (da) 2019-07-22
US12012452B2 (en) 2024-06-18
PL2700651T3 (pl) 2019-09-30
JP2011528551A (ja) 2011-11-24
EP2321352A1 (en) 2011-05-18
PE20110385A1 (es) 2011-06-22
KR20110041527A (ko) 2011-04-21
ME02396B (me) 2016-08-31
IL210413A (en) 2017-04-30
PT2321352E (pt) 2016-03-18
US20120201814A1 (en) 2012-08-09
CL2011000117A1 (es) 2011-06-17
EA201100239A1 (ru) 2011-10-31
PE20140852A1 (es) 2014-07-14
US8168759B2 (en) 2012-05-01
IL210413A0 (en) 2011-03-31
CN105936648A (zh) 2016-09-14
US20100028354A1 (en) 2010-02-04
AU2009270726A1 (en) 2010-01-21
SMT201600090B (it) 2016-04-29
EP2700651B1 (en) 2019-04-10
SI2321352T1 (sl) 2016-04-29
US10919965B2 (en) 2021-02-16
HK1155178A1 (zh) 2012-05-11
IL251320A0 (en) 2017-05-29
CL2012002428A1 (es) 2013-01-11
TW201336510A (zh) 2013-09-16
TW201006494A (en) 2010-02-16
US20150299321A1 (en) 2015-10-22
CA2731220C (en) 2017-10-10
PT2700651T (pt) 2019-06-19
HRP20190966T1 (hr) 2019-07-26
CA2731220A1 (en) 2010-01-21
KR20160113322A (ko) 2016-09-28
RS58904B1 (sr) 2019-08-30
CO6341641A2 (es) 2011-11-21
US9908937B2 (en) 2018-03-06
CY1121796T1 (el) 2020-07-31
US20210047414A1 (en) 2021-02-18
SI2700651T1 (sl) 2019-08-30
HRP20160329T1 (hr) 2016-04-22
JP2015120695A (ja) 2015-07-02
JP2016063830A (ja) 2016-04-28
IL251320B (en) 2019-01-31
KR101660057B1 (ko) 2016-09-26
US20180142023A1 (en) 2018-05-24
EP2321352B1 (en) 2016-01-06
HUE045249T2 (hu) 2019-12-30
RS54675B1 (sr) 2016-08-31
SMT201900367T1 (it) 2019-09-09
LT2700651T (lt) 2019-06-25
PL2321352T3 (pl) 2016-06-30
JP6058833B2 (ja) 2017-01-11
ES2562629T3 (es) 2016-03-07
EA024585B1 (ru) 2016-10-31
US9085629B2 (en) 2015-07-21
TWI450725B (zh) 2014-09-01

Similar Documents

Publication Publication Date Title
AR072571A1 (es) Composiciones monovalentes para union a cd28 y procedimientos de uso
AR073459A1 (es) Composiciones de dominios variables de anticuerpos monovalentes para la union de cd28 y metodos de uso
MX2021000398A (es) Moleculas de anticuerpo que se unen a pd-l1 y cd137.
BR112012023010A8 (pt) Anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37
MX2016012094A (es) Composiciones de anticuerpos para tratamiento tumoral.
CL2020000452A1 (es) Anticuerpos de b7-h4 y métodos para usarlos.
BR112022009723A2 (pt) Anticorpos específicos para cd47, pd-l1, e usos dos mesmos
AR077333A1 (es) Anticuerpos humanos de alta afinidad para la angiopoyetina -2 humana
BR112019000970A2 (pt) proteínas de ligação ao antígeno multiespecíficas e métodos de uso das mesmas
CY1119925T1 (el) Aνti-cd40 αντισωματα, χρησεις και μεθοδοι
MX369276B (es) Agentes para tratamiento de enfermedades cancerosas que expresan claudina.
AR098465A1 (es) ANTICUERPOS ANTI-a-SINUCLEÍNA Y MÉTODOS DE UTILIZACIÓN
CO2018003852A2 (es) Proteínas de unión a antigeno que activan el receptor de leptina
AR084315A1 (es) Anticuerpos anti-notch1
CO2017011486A2 (es) Anticuerpos heterodiméricos que se unen a cd3 y a antígenos tumorales
BR112015014751A2 (pt) anticorpos anti-tau humanos
AR085600A1 (es) Agentes de union biespecifica
BR112014007382A2 (pt) anticorpos anti-erbb3 e seus usos
MX2014001799A (es) Anticuerpos sin fc qie comprenden dos fragmentos fab y metodos de uso.
CO6280500A2 (es) Anticuerpos humanizados especificos pare l factor von willebrand
PE20141158A1 (es) El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapeutico
BR112013007314A2 (pt) anticorpos anti-cd48 e seus usos
PE20091520A1 (es) Anticuerpos bivalentes biespecificos
EA201390472A1 (ru) Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты
MX2016006709A (es) Moduladores de aplnr y usos de estos.

Legal Events

Date Code Title Description
FG Grant, registration